US 7,320,974 B2
Cytoskeletal active compounds, compositions and use
John W. Lampe, Cary, N.C. (US); Robert Plourde, Jr., Chapel Hill, N.C. (US); Jin She, Chapel Hill, N.C. (US); Jason L. Vittitow, Durham, N.C. (US); Paul S. Watson, Carrboro, N.C. (US); Michael T. Crimmins, Chapel Hill, N.C. (US); and David J. Slade, Durham, N.C. (US)
Assigned to Inspire Pharmaceuticals, Inc., Durham, N.C. (US)
Filed on Mar. 23, 2006, as Appl. No. 11/389,665.
Claims priority of provisional application 60/665408, filed on Mar. 25, 2005.
Prior Publication US 2006/0217427 A1, Sep. 28, 2006
Int. Cl. A61K 31/351 (2006.01); A61K 31/357 (2006.01); C07D 309/06 (2006.01); C07D 313/02 (2006.01); C07D 313/16 (2006.01)
U.S. Cl. 514—211.09  [514/450; 540/451; 540/456; 540/468; 548/182] 26 Claims
 
1. A compound of Formula I, or pharmaceutically-acceptable salts, tautomers, solvates, or hydrates thereof:

OG Complex Work Unit Drawing
wherein:
X1═S;
Y1═NR6;
Y2═O;
Z1═absent;
Q1 and Q2 are independently O or S;
A1 and A2 are independently hydrogen, halo, alkyl, or alkoxy, optionally substituted;
n═1;
R1, R2 and R6 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, or heterocycle, optionally substituted;
with a proviso that R1 is not 3-monomethyl-substituted.